MedTrace Logo

Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

NCT01511692 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2017-01-25

No results posted yet for this study

Summary

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects of liraglutide on energy intake in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

liraglutide

1.8 mg/day injected subcutaneously for 4 weeks

DRUG

placebo

Liraglutide placebo, injected subcutaneously for 4 weeks

DRUG

placebo

Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks

DRUG

glimepiride

Dose individually adjusted, administered orally for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • Australia
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01511692 on ClinicalTrials.gov